Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
521-540 of 936 trials

Acute Myeloid Leukemia: JNJ-89853413 Study

We are testing a new treatment for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms. The goal is to evaluate its safety and how it may help those who have not responded to other therapies.

Relapsed or Refractory Acute Myeloid LeukemiaMyelodysplastic Syndrome>2 yearsSafety phase (I)Hematology

KO-2806 for Advanced Solid Tumors

We are studying the effects of KO-2806, both alone and with other treatments, in patients with advanced solid tumors. This research aims to find out how well it works in managing their condition.

Colorectal CancerPancreatic Ductal AdenocarcinomaRenal Cell Carcinoma>2 yearsSafety phase (I)Oncology

Advanced Solid Cancers: BAY 3498264 Study

We are investigating a new treatment for patients with advanced solid cancers that have the KRASG12C mutation. The study looks at how this treatment works alone and with another medication.

Advanced Solid Tumors with KRAS Mutation>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: CXCR4 PET Tracer Study

We are testing a new radiopharmaceutical to see how it works in patients with advanced solid tumors. This study aims to understand its effects on the body and how it can help in future treatments.

Advanced Solid Tumor6-12 monthsSafety phase (I)Oncology

Relapsed or Refractory PCNSL: Emavusertib Study

We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.

Hematological MalignancyPrimary Central Nervous System Lymphoma (PCNSL)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Lupus Nephritis: KYV-101 CAR T-Cell Therapy

We are testing a new immune cell therapy for individuals with refractory lupus nephritis. The goal is to see if it can improve kidney function in patients who have not responded to other treatments.

Lupus Nephritis>2 yearsSafety phase (I)Efficacy phase (II)NephrologyRheumatology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Osteoarthritis: Safety of Lipiodol Embolization

We are assessing the safety of Lipiodol embolization for patients with hard-to-treat symptomatic osteoarthritis. This study aims to understand if this treatment can be a viable option for those not responding to conventional therapies.

Digital OsteoarthritisSafety phase (I)Internal MedicineOrthopedics and Traumatology

Inflammatory Bowel Disease and Rheumatoid Arthritis: Adalimumab Imaging Study

We are exploring how well a drug called adalimumab spreads in inflamed tissues using advanced imaging technology. This study aims to improve our understanding of drug distribution in patients with inflammatory bowel disease and rheumatoid arthritis.

Crohn's DiseaseSpondyloarthritisRheumatoid ArthritisSafety phase (I)GastroenterologyRheumatology

Advanced Cancer: RO7759065 and Atezolizumab Study

We are investigating a new treatment combining RO7759065 with Atezolizumab for individuals with locally advanced or metastatic cancer. The goal is to understand how safe and effective this combination is for patients.

Locally Advanced or Metastatic Solid TumorsSafety phase (I)Oncology

High-Grade Glioma: New Imaging Technique

We are testing a new method using special dyes to help surgeons better identify and remove tumors in patients with high-grade glioma. This study aims to refine how we assess tumor margins during surgery.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Renal Impairment: Enpatoran Study

We are investigating how kidney function impacts the way the drug Enpatoran is absorbed and used in the body. This study aims to improve treatment for patients with renal impairment.

Healthy Participants1-2 yearsSafety phase (I)Internal MedicineNephrology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

NK Cell Infusion for Sarcoma in Young Patients

We are testing a new immunotherapy using activated NK cells for children, adolescents, and young adults with refractory sarcomas. The goal is to evaluate its safety and effects after chemotherapy or radiotherapy.

Sarcomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Multiple Myeloma: JNJ-87562761 Treatment

We are testing a new drug for patients with relapsed or refractory multiple myeloma. The goal is to understand its safety and how it affects the disease.

Relapsed/Refractory Multiple MyelomaSafety phase (I)HematologyOncology

Metamizole and Imatinib Interaction Study

We are investigating how the pain reliever metamizole impacts the way the body processes imatinib in healthy volunteers. This research may help improve treatment strategies for patients using these medications.

Healthy Participants6-12 monthsSafety phase (I)Internal MedicineOncology

M9466 for Advanced Solid Tumors

We are investigating the effects of M9466, both alone and with other treatments, in patients with advanced solid tumors. This study aims to find out how well it works in this patient group.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Amlitelimab: Effects on Medication Processing

We are investigating how amlitelimab influences the way the body handles specific medications. This study aims to improve safety for patients taking multiple drugs.

Atopic Dermatitis1-2 yearsSafety phase (I)DermatologyInternal Medicine

Advanced Solid Tumors: MOMA-313 Oral Medication

We are studying an oral treatment called MOMA-313 for individuals with advanced or metastatic solid tumors. The goal is to learn more about its effects and potential benefits.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Oncology

Advanced Sarcoma: NKG2D CAR-T Cell Therapy

We are testing a new type of immune cell therapy for children and young adults with advanced sarcoma. The study aims to see if this treatment is safe and effective in reducing tumor size.

Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology